IPSC
NASDAQ · Biotechnology
Century Therapeutics Inc
$2.45
+0.04 (+1.66%)
Financial Highlights (FY 2026)
Revenue
227.46M
Net Income
-19,965,277
Gross Margin
—
Profit Margin
-8.8%
Rev Growth
+175.9%
D/E Ratio
—
Revenue & Net Income
Margin Trends
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| Gross Margin | — | 60.2% | 60.2% | 60.2% |
| Operating Margin | -15.8% | -6.1% | -7.1% | -6.4% |
| Profit Margin | -8.8% | -5.7% | -4.7% | -6.0% |
Income Statement
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| Revenue | 227.46M | 24.41M | 24.82M | 19.44M |
| Gross Profit | — | 14.70M | 14.94M | 11.70M |
| Operating Income | -35,984,723 | -1,494,470 | -1,758,509 | -1,253,487 |
| Net Income | -19,965,277 | -1,389,193 | -1,166,783 | -1,174,826 |
| Gross Margin | — | 60.2% | 60.2% | 60.2% |
| Operating Margin | -15.8% | -6.1% | -7.1% | -6.4% |
| Profit Margin | -8.8% | -5.7% | -4.7% | -6.0% |
| Rev Growth | +175.9% | +22.2% | +16.0% | +16.0% |
Balance Sheet
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| Total Debt | 0 | 27.74M | 29.45M | 33.99M |
| Total Equity | — | 103.32M | 95.78M | 103.82M |
| D/E Ratio | — | 0.27 | 0.31 | 0.33 |
Cash Flow
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| EBITDA | -8,693,101 | -1,777,503 | -1,974,923 | -1,572,213 |
| Free Cash Flow | — | -1,484,406 | -1,631,995 | -1,127,049 |